<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03971201</url>
  </required_header>
  <id_info>
    <org_study_id>20190507</org_study_id>
    <nct_id>NCT03971201</nct_id>
  </id_info>
  <brief_title>A Randomized Phase II Trial of Surgery Plus Sorafenib vs. Sorafenib Alone for Hepatocellular Cancer (HCC) With Portal Vein Invasion</brief_title>
  <official_title>A Randomized Phase II Trial of Surgery Plus Sorafenib vs. Sorafenib Alone for Hepatocellular Cancer (HCC) With Portal Vein Invasion</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>White Plains Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Eastern Hepatobiliary Surgery Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Sun Yat-sen University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>West China Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Cancer Hospital of Guangxi Medical University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Anhui Provincial Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Fujian Cancer Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Wenzhou People's Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>White Plains Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Patients with HCC with portal vein involvement not involving the bifurcation (vP1-vP3) and no&#xD;
      evidence of extra-hepatic spread will be enrolled. Patients will be required to have Child's&#xD;
      A liver function and no significant portal hypertension. Patients will be randomly assigned&#xD;
      with a 1:1 ratio to either surgery followed by adjuvant sorafenib or sorafenib alone.&#xD;
      Patients will be followed by serial imaging. The primary end-point is overall survival.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Trial design&#xD;
&#xD;
      Surgery + sorafenib vs. sorafenib 100 patients per arm Centralized randomization by CRO Need&#xD;
      to call CRO for treatment allocation Primary end-point - OS Secondary end-point Progression&#xD;
      free survival (PFS) Randomized 1:1 Stratification Vp1-2 vs. Vp3 AFP ≤400 vs AFP &gt;400&#xD;
      Intention to treat Surgery aborted or R1-2 resection will remain in surgical arm No cross&#xD;
      over CT scan chest/abdomen 4 weeks after surgery as post-operative baseline Will not alter&#xD;
      treatment allocation Will allow for PFS measurement in surgical arm CT scan chest/abdomen&#xD;
      pelvis Q 12 weeks after initiation sorafenib Patients progressing on sorafenib allowed 2nd&#xD;
      line treatment Regorafenib or lenvatinib - if approved in China Dose reduction sorafenib as&#xD;
      per protocol&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">September 6, 2019</start_date>
  <completion_date type="Anticipated">June 30, 2023</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2022</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>overall survival</measure>
    <time_frame>2-3 year</time_frame>
    <description>time from randomization to death</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>progression free survival</measure>
    <time_frame>3-12 months</time_frame>
    <description>time from initiation of intervention until progression as defined by RESIST</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">200</enrollment>
  <condition>Hepatocellular Cancer</condition>
  <arm_group>
    <arm_group_label>Surgery plus sorafenib</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>surgical resection followed by adjuvant sorafenib</description>
  </arm_group>
  <arm_group>
    <arm_group_label>sorafenib only</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>sorafenib only</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>hepatic resection</intervention_name>
    <description>removal of portion of liver containing cancer</description>
    <arm_group_label>Surgery plus sorafenib</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Sorafenib</intervention_name>
    <description>sorafenib either as adjuvant therapy after resection or as only treatment</description>
    <arm_group_label>Surgery plus sorafenib</arm_group_label>
    <arm_group_label>sorafenib only</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        Diagnosis of HCC A) 1st diagnosis of HCC - no prior treatments of HCC B) Diagnosis made by&#xD;
        contrast enhanced CT or MRI with arterial and portal phases&#xD;
&#xD;
          1. Arterial enhancement&#xD;
&#xD;
          2. Venous washout&#xD;
&#xD;
          3. Expanding/enhancing tumor thrombus seen in portal vein Extent of HCC spread A) Vp1-3&#xD;
             (Japanese system) - VP1-2 (Cheng criteria - Shanghai) B) No involvement of main portal&#xD;
             vein Vp4 (Japanese system) - Vp3 Shanghai C) No evidence of extra-hepatic spread in&#xD;
             abdomen D) No evidence of hepatic vein or vena cava invasion Need for Biopsy A)&#xD;
             Patients not meeting above criteria B) Absence of underlying liver disease&#xD;
             Demographics A) Age ≥ 18 Women of reproductive age A) Negative pregnancy test B) Must&#xD;
             be on birth control for duration of study Able to provide informed consent No prior&#xD;
             malignancy A) Excluding basal/squamous cell skin cancers B) Excluding superficial&#xD;
             bladder cancer C) Excluding cervical cancer Underlying liver disease A) HBV, HCV,&#xD;
             alcohol, or none B) All HBV patients must be placed on anti-viral therapy prior to any&#xD;
             treatment and continue through entire study C) Co-infection HBV with HCV excluded D)&#xD;
             HIV infection excluded Liver function/Performance status A) Child's A or B7 liver&#xD;
             function B) Absence of clinical portal hypertension&#xD;
&#xD;
        a. Platelet count ≥ 100,000 b. No evidence of varices or splenomegaly on imaging c. No&#xD;
        ascites ECOG performance status 0-1 Tumor characteristics A) Size of largest tumor ≤ 10cm&#xD;
        B) &lt;50% of liver volume involved by tumor C) Multiple tumors allowed D) All tumors all&#xD;
        confined to same lobe as PV involvement E) Hepatic Vein or Inferior Vena Cava involvement&#xD;
        excluded Non-contrast CT of chest A) No lung metastases B) Involvement of gallbladder and&#xD;
        diaphragm allowed C) Involvement of omentum allowed D) Involvement of abdominal wall&#xD;
        allowed E) Involvement of colon, stomach, duodenum excluded&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        Unable to provide informed consent Age &lt;18 years Unable to take anti-viral medication for&#xD;
        hepatitis B Unable to take sorafenib Medically unfit for surgery Prior malignancy other&#xD;
        than those specifically allowed by study Prior treatment of HCC Tumor characteristics A)&#xD;
        HCC &gt;10cm B) Bilobar tumor C) Mixed cholangiocarcinoma HCC D) Extra-hepatic tumor E) Tumor&#xD;
        involving stomach, duodenum or colon F) Tumor involving hepatic veins or vena cava G) Tumor&#xD;
        involving portal vein bifurcation&#xD;
&#xD;
        Liver disease A) Liver function decompensated beyond Child's B7 B) Significant portal&#xD;
        hypertension - splenomegaly, varices, ascites or platelet count &lt;100,000 C) Co-infection&#xD;
        with HBV and HCV D) Co-infection with HIV ECOG performance status &gt;1&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Wei-Hua Guan, MD</last_name>
    <phone>+8613501673307</phone>
    <email>weiyu.wang@tigermed.net</email>
  </overall_contact>
  <location>
    <facility>
      <name>Eastern Hepatobiliary Surgery Hospital</name>
      <address>
        <city>Shanghai</city>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Shuqun Cheng, MD</last_name>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>April 2021</verification_date>
  <study_first_submitted>May 31, 2019</study_first_submitted>
  <study_first_submitted_qc>May 31, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">June 3, 2019</study_first_posted>
  <last_update_submitted>April 8, 2021</last_update_submitted>
  <last_update_submitted_qc>April 8, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">April 14, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>portal vein invasion</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Liver Neoplasms</mesh_term>
    <mesh_term>Carcinoma, Hepatocellular</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sorafenib</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
    <ipd_description>Data will not be shared</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

